What hematologic condition presents with thrombocytosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Essential Thrombocythemia (ET) is the Primary Hematologic Condition Presenting with Thrombocytosis

Essential thrombocythemia is the most common primary hematologic condition presenting with sustained thrombocytosis (platelet count ≥450 × 10⁹/L), though secondary causes account for the majority (83%) of all thrombocytosis cases. 1, 2, 3

Differential Diagnosis Framework

When evaluating thrombocytosis, you must systematically distinguish between:

Primary (Clonal) Causes

  • Essential thrombocythemia - most common primary cause
  • Polycythemia vera (PV)
  • Primary myelofibrosis (PMF), including prefibrotic PMF
  • Chronic myeloid leukemia (CML) - rare presentation 4
  • Myelodysplastic syndromes with ring sideroblasts and thrombocytosis

Secondary (Reactive) Causes

The most frequent secondary causes are 3:

  • Tissue injury (32.2%)
  • Infection (17.1%)
  • Chronic inflammatory disorders (11.7%)
  • Iron deficiency anemia (11.1%)
  • Malignancy
  • Post-splenectomy state

Diagnostic Approach to Essential Thrombocythemia

The diagnosis of ET requires meeting all four WHO criteria 1:

  1. Sustained platelet count ≥450 × 10⁹/L (lowered from the previous 600 × 10⁹/L threshold to improve early detection)

  2. Bone marrow biopsy showing:

    • Proliferation mainly of megakaryocytic lineage
    • Increased numbers of enlarged, mature megakaryocytes in loose clusters
    • No significant increase or left-shift of neutrophil granulopoiesis or erythropoiesis
    • Minimal or absent reticulin fibrosis
  3. Exclusion of other WHO-defined myeloid neoplasms:

    • Not meeting criteria for PV, PMF, CML, or MDS
    • Critical pitfall: Must exclude occult PV in iron-deficient patients through iron replacement trial 1
    • Must exclude prefibrotic PMF through careful bone marrow histologic assessment
  4. Demonstration of clonality:

    • JAK2V617F mutation (present in ~50% of ET patients) 1
    • OR CALR mutation
    • OR MPL mutation
    • OR another clonal marker
    • OR in mutation-negative patients, absence of evidence for reactive thrombocytosis

Molecular Testing Strategy

Approximately 80% of ET patients express driver mutations in a mutually exclusive manner 2:

  • JAK2V617F - ~50-60%
  • CALR - ~20-25%
  • MPL - ~3-5%
  • Triple-negative - ~10-15%

Testing sequence: Start with JAK2V617F; if negative, proceed to CALR and MPL testing 5. Additional mutations found in ~50% include TET2 (9-11%), ASXL1 (7-20%), DNMT3A (7%), and SF3B1 (5%) 2.

Clinical Significance and Risk Stratification

Primary thrombocytosis carries significantly higher thrombotic risk than secondary thrombocytosis 3. The median platelet count is higher in primary versus secondary causes.

Thrombotic Risk Stratification (IPSET Criteria) 6

Calculate risk score based on:

  • Age >60 years: 1 point
  • Cardiovascular risk factors: 1 point
  • Previous thrombosis: 2 points
  • JAK2V617F mutation: 2 points

Risk categories:

  • Low risk: Score 0-1
  • Intermediate risk: Score 2
  • High risk: Score ≥3

Refined Risk Categories 2, 5

  • Very low: Age ≤60 years, no thrombosis history, JAK2 wild-type
  • Low: Same as very low but JAK2 mutation present
  • Intermediate: Age >60 years with JAK2 wild-type
  • High: Thrombosis history OR age >60 years with JAK2 mutation

Prognostic Implications

Life expectancy is reduced compared to the general population. Median survival is approximately 18 years overall but exceeds 35 years in younger patients 2.

Key prognostic mutations:

  • MPL and CALR-1: Increased risk of myelofibrosis transformation
  • Spliceosome mutations: Inferior overall and MF-free survival
  • TP53: Leukemic transformation risk
  • JAK2V617F: Associated with thrombosis risk

Leukemic transformation rate at 10 years is <1% but may be higher with JAK2 mutation plus extreme thrombocytosis or abnormal karyotype 2.

Common Diagnostic Pitfalls

  1. Missing occult PV: Always perform iron replacement trial in iron-deficient patients before excluding PV 1
  2. Overlooking prefibrotic PMF: Requires expert bone marrow histology review - prefibrotic PMF has different prognosis and management
  3. Assuming reactive cause without confirmation: In JAK2-negative patients with normal bone marrow, must rigorously exclude all reactive causes 1
  4. Using outdated platelet threshold: The current threshold is ≥450 × 10⁹/L, not 600 × 10⁹/L 1, 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.